What imaging studies and laboratory tests should be ordered for surveillance in a 47‑year‑old woman who underwent curative resection and completed adjuvant chemotherapy for colon cancer?

Surveillance Protocol for Post-Treatment Colon Cancer

For this 47-year-old woman who completed curative surgery and adjuvant chemotherapy, order CEA testing every 3-6 months for 5 years, annual CT chest/abdomen for 3 years, and colonoscopy at 1 year post-surgery. 1

Blood Tests

CEA (Carcinoembryonic Antigen):

• Every 3-6 months for the first 5 years 1
• More frequent testing (every 3 months) is reasonable for higher-risk patients, as 80% of recurrences occur within the first 2-2.5 years 1
• CEA monitoring has been associated with increased rates of curative surgical resection when recurrence is detected 2

Important caveat: While CEA is recommended, it has limitations—in one study, CEA elevation alone detected only 3 of 15 recurrences (20% sensitivity) 3. However, when combined with imaging, the detection rate improves to 73.3% 3.

Imaging Studies

CT Chest and Abdomen:

• Annually for 3 years 1
• For high-risk patients (stage III, inadequate lymph node harvest <12 nodes, high-risk features), consider every 6-12 months for the first 3 years 1
• CT imaging has demonstrated improved overall mortality compared to no imaging in most analyses 2
• The combination of CT imaging with CEA provides superior recurrence detection compared to either modality alone 3

What NOT to order:

• PET scans are NOT recommended for routine surveillance outside clinical trials 1
• Blood-based ctDNA testing, while emerging, currently shows lower sensitivity than standard imaging plus CEA (53.3% vs 73.3%) and should not replace conventional surveillance 3

Colonoscopy

Timing:

• At 1 year post-surgery (approximately) 1
• If a complete preoperative colonoscopy was not performed, do this as soon as reasonable after completing chemotherapy rather than waiting for the 1-year mark 1
• Subsequent colonoscopies every 5 years if findings are normal 1

Key consideration: The 1-year surveillance colonoscopy has a low yield—detecting adenocarcinoma in only 0.44% and advanced adenomas in 0.66% of patients 4. However, it remains guideline-recommended to detect metachronous lesions.

Clinical Visits

Medical history and physical examination:

• Every 3-6 months for 5 years 1
• Focus on new, persistent, or worsening symptoms that could indicate recurrence 1
• After 5 years, only 5% of recurrences occur, so surveillance intensity can decrease 1

Risk Stratification Matters

Adjust surveillance intensity based on:

• Stage (stage III requires more intensive monitoring than stage II)
• Lymph node harvest adequacy (<12 nodes examined is an adverse prognostic factor) 5
• High-risk features (T4 tumors, perforation, obstruction, poorly differentiated histology)
• Patient functional status—if the patient cannot tolerate aggressive treatment for recurrence, surveillance testing should not be performed 1

Critical Pitfall to Avoid

Do not perform surveillance in patients who are not surgical or systemic therapy candidates due to severe comorbidities 1. Surveillance is only beneficial when early detection would lead to curative-intent treatment. Testing without the ability to act on results causes harm without benefit.

Timeline Summary

Years 1-2 (highest risk period):

• CEA every 3 months
• CT chest/abdomen annually
• Colonoscopy at 1 year
• Clinical visits every 3 months

Years 3-5:

• CEA every 3-6 months
• CT chest/abdomen at year 3 (last one)
• Clinical visits every 3-6 months
• Colonoscopy at year 5 (if 1-year scope was normal)

After 5 years:

• Surveillance can be discontinued for most patients, as 95% of recurrences occur by this point 1
• Continue colonoscopy every 5 years for polyp surveillance